American Society of Hematology

Figure 2.

$RR MM patients who received anti-MM treatment <1 month prior to BM biopsy are most sensitive to HexaBody-DR5/DR5. (A) MM cell kill (%) by HexaBody-DR5/DR5 (20 µg/mL) of BM samples from ND (n = 13) and RR (n = 35) patients, including daratumumab-refractory (Dara-R) patients (n = 8). *P = .0246 (ND vs total RR group). (B) MM cell kill (%) by HexaBody-DR5/DR5 (20 µg/mL) of BM samples from RR patients who had received their last exposure to therapy >1 month (n = 14) and ≤1 month (n = 17) prior to their BM biopsy. *P = .0116. Data are shown as median; error bars indicate the interquartile range. Statistical analyses were performed with a Mann-Whitney U test.$

RR MM patients who received anti-MM treatment <1 month prior to BM biopsy are most sensitive to HexaBody-DR5/DR5. (A) MM cell kill (%) by HexaBody-DR5/DR5 (20 µg/mL) of BM samples from ND (n = 13) and RR (n = 35) patients, including daratumumab-refractory (Dara-R) patients (n = 8). *P = .0246 (ND vs total RR group). (B) MM cell kill (%) by HexaBody-DR5/DR5 (20 µg/mL) of BM samples from RR patients who had received their last exposure to therapy >1 month (n = 14) and ≤1 month (n = 17) prior to their BM biopsy. *P = .0116. Data are shown as median; error bars indicate the interquartile range. Statistical analyses were performed with a Mann-Whitney U test.

This Feature Is Available To Subscribers Only